Windlas Biotech cash flow

Latest FY26

Cash from operations: ₹105cr+53.8% on FY25
Capital spending: ₹67.7cr+29.6% on FY25
Free cash flow: ₹37.3cr+132.3% on FY25
Cash from financing: −₹13.0cr₹1.0 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	30.7	28.0	13.4	12.4
	—	4.8	4.4	1.1	0.8
	—	−1.2	−1.5	−2.0	−3.5
	—	−0.6	0.0	0.0	0.0
	—	17.7	2.7	4.8	3.3
	—	−14.8	−15.1	−10.8	−5.7
	—	19.6	−19.2	12.5	−16.0
	—	−61.0	−30.8	−19.8	−8.4
	—	0.4	−0.5	0.2	1.5
	—	−1.2	−0.1	−0.5	0.8
	—	−24.2	−7.1	2.3	−3.2
	—	0.1	−0.0	−0.2	−0.0
	—	60.7	36.1	43.7	24.5
	—	8.9	4.1	4.8	3.9
	—	0.0	−0.1	−0.1	0.1
	—	−7.6	8.1	0.5	2.6
	—	0.4	0.1	0.3	0.1
	—	0.4	0.6	0.2	0.5
Cash from operating activities
	86.6	86.9	79.4	77.0	57.1
	—	33.1	9.7	50.5	13.6
	—	120	89.1	128	70.7
	—	15.1	20.9	18.6	9.7
	—	105	68.2	109	61.0
Cash from investing activities
	—	67.7	52.2	37.7	70.9
	—	0.0	0.2	0.0	0.9
	—	30.2	34.9	56.1	36.9
	—	−4.8	−11.2	0.1	−88.2
	—	1.3	1.6	1.7	4.6
	—	−91.8	−74.1	−92.1	−14.1
Cash from financing activities
	—	0.0	0.0	−4.0	−27.2
	—	4.0	4.4	0.0	0.0
	—	2.8	27.0	0.0	0.0
	—	0.0	0.0	0.3	5.7
	—	2.9	14.5	1.5	1.3
	—	4.8	4.4	1.1	0.8
	—	12.2	11.5	8.3	7.6
	—	0.0	0.0	0.0	−1.1
	—	−13.0	1.0	−15.3	−43.7
	—	0.1	−4.8	1.6	3.1
	—	0.1	−4.8	1.6	3.1
	—	—	—	5.2	3.7
Reference items
	105	105	94.1	78.1	60.2
	11.1%	11.6%	12.4%	12.4%	11.7%
	37.3	37.3	16.0	71.2	−9.9
	—	35.2	38.7	69.8	—
	₹17.66	₹17.66	₹7.60	₹33.75	−₹4.69
	50.34×	—	—	—	—
	—	1.58×	1.13×	1.87×	1.43×
	—	15.1	20.9	18.6	9.7
	—	4.8	4.4	1.1	0.8

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

WINDLAS₹888.70

Windlas Biotech Limited

· Pharma & Health

₹ CrorePeersHESTERBIO INDOCO SAIPARENT SYNCOMF PANACEABIO NGLFINE HIKAL JAGSNPHARMMcap ₹1,876 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	12.4	13.4	28.0	30.7	—
+ Finance Costs	0.8	1.1	4.4	4.8	—
+ Interest Income	-3.5	-2.0	-1.5	-1.2	—
+ Unrealised FX (Gain) / Loss	0.0	0.0	0.0	-0.6	—
+ Other Non-cash Items	3.3	4.8	2.7	17.7	—
+ Other Reconciling Items	-5.7	-10.8	-15.1	-14.8	—
Changes in Working Capital
+ Inventories	-16.0	12.5	-19.2	19.6	—
+ Trade Receivables — Current	-8.4	-19.8	-30.8	-61.0	—
+ Other Financial Assets — Current	1.5	0.2	-0.5	0.4	—
+ Other Financial Assets — Non-current	0.8	-0.5	-0.1	-1.2	—
+ Other Current Assets	-3.2	2.3	-7.1	-24.2	—
+ Other Non-current Assets	-0.0	-0.2	-0.0	0.1	—
+ Trade Payables — Current	24.5	43.7	36.1	60.7	—
+ Other Financial Liabilities — Current	3.9	4.8	4.1	8.9	—
+ Other Financial Liabilities — Non-current	0.1	-0.1	-0.1	0.0	—
+ Other Current Liabilities	2.6	0.5	8.1	-7.6	—
+ Provisions — Current	0.1	0.3	0.1	0.4	—
+ Provisions — Non-current	0.5	0.2	0.6	0.4	—
Cash from Operating Activities
Profit Before Tax (per I/S)	57.1	77.0	79.4	86.9	86.6
+ Total Adjustments (incl. Working Capital)	13.6	50.5	9.7	33.1	—
Cash from Operations (pre-tax)	70.7	127.5	89.1	120.1	—
+ Income Taxes Paid	9.7	18.6	20.9	15.1	—
Cash from Operating Activities	61.0	108.9	68.2	104.9	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	70.9	37.7	52.2	67.7	—
+ Disp of Fixed Assets	0.9	0.0	0.2	0.0	—
+ Acq of Investment Property	36.9	56.1	34.9	30.2	—
+ Acq of Other Long-term Assets	-88.2	0.1	-11.2	-4.8	—
+ Interest Received — Investing	4.6	1.7	1.6	1.3	—
Cash from Investing Activities	-14.1	-92.1	-74.1	-91.8	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	-27.2	-4.0	0.0	0.0	—
+ Proceeds from Exercise of Stock Options	0.0	0.0	4.4	4.0	—
+ Proceeds from Borrowings	0.0	0.0	27.0	2.8	—
+ Repayment of Borrowings	5.7	0.3	0.0	0.0	—
+ Payment of Lease Liabilities	1.3	1.5	14.5	2.9	—
+ Interest Paid	0.8	1.1	4.4	4.8	—
+ Dividends Paid	7.6	8.3	11.5	12.2	—
+ Other Inflows / (Outflows) — Financing	-1.1	0.0	0.0	0.0	—
Cash from Financing Activities	-43.7	-15.3	1.0	-13.0	—
Net Changes in Cash (pre-FX)	3.1	1.6	-4.8	0.1	—
Net Changes in Cash	3.1	1.6	-4.8	0.1	—
Closing Cash	3.7	5.2	—	—	—
Reference Items
EBITDA	60.2	78.1	94.1	104.7	104.9
EBITDA Margin %	11.74	12.38	12.39	11.58	11.13
Free Cash Flow (CFO − Capex)	-9.9	71.2	16.0	37.3	37.3
Free Cash Flow to Equity	—	69.8	38.7	35.2	—
Free Cash Flow per Basic Share	-4.69	33.75	7.60	17.66	17.66
Price to Free Cash Flow	—	—	—	—	50.34
Cash Flow to Net Income	1.43	1.87	1.13	1.58	—
Cash Paid for Taxes	9.7	18.6	20.9	15.1	—
Cash Paid for Interest	0.8	1.1	4.4	4.8	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.